KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Taxes (2016 - 2022)

Pacira BioSciences has reported Current Taxes over the past 9 years, most recently at $11000.0 for Q2 2022.

  • Quarterly results put Current Taxes at $11000.0 for Q2 2022, changed N/A from a year ago — trailing twelve months through Jun 2022 was $11000.0 (changed N/A YoY), and the annual figure for FY2021 was $429000.0, up 276.32%.
  • Current Taxes for Q2 2022 was $11000.0 at Pacira BioSciences, down from $863000.0 in the prior quarter.
  • Over the last five years, Current Taxes for PCRX hit a ceiling of $1.7 million in Q1 2020 and a floor of $11000.0 in Q2 2022.
  • Median Current Taxes over the past 5 years was $343000.0 (2019), compared with a mean of $534200.0.
  • Peak annual rise in Current Taxes hit 1970.51% in 2020, while the deepest fall reached 91.45% in 2020.
  • Pacira BioSciences' Current Taxes stood at $90000.0 in 2018, then soared by 1381.11% to $1.3 million in 2019, then plummeted by 91.45% to $114000.0 in 2020, then skyrocketed by 276.32% to $429000.0 in 2021, then plummeted by 97.44% to $11000.0 in 2022.
  • The last three reported values for Current Taxes were $11000.0 (Q2 2022), $863000.0 (Q1 2022), and $429000.0 (Q4 2021) per Business Quant data.